High Flow Nasal Cannula Market worth $1.44 billion by 2031
The report "High Flow Nasal Cannula Market by Product (Systems, Consumables & Accessories (Humidifiers, Interfaces)), Patient Type (Neonatal & Pediatric), Application (Acute Respiratory Failure, COPD), End User (Hospitals), & Region - Global Forecast to 2031", is projected to grow from USD 0.94 billion in 2026 and to reach USD 1.44 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 8.9% during the forecast period.
Browse 300 market data Tables and 50 Figures spread through 330 Pages and in-depth TOC on "High Flow Nasal Cannula Market by Product (Systems, Consumables & Accessories (Humidifiers, Interfaces)), Patient Type (Neonatal & Pediatric), Application (Acute Respiratory Failure, COPD), End User (Hospitals), & Region - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/high-flow-nasal-cannula-market-223257171.html
The HFNC market is expanding due to the rising prevalence of acute and chronic respiratory diseases, increasing incidence of acute hypoxemic respiratory failure, and growing demand for non-invasive respiratory support. HFNC therapy offers several clinical advantages, including the delivery of heated and humidified oxygen at high flow rates, improved oxygenation, reduced work of breathing, upper-airway dead-space clearance, and enhanced secretion management. Its higher level of patient comfort and tolerance compared with conventional oxygen therapy and certain NIV approaches is also encouraging greater adoption in clinical practice. Furthermore, the increasing use of HFNC across intensive care units, emergency departments, post-extubation management, pre-oxygenation before intubation, perioperative care, bronchoscopy, and during NIV or CPAP breaks is creating additional demand. Growing clinical acceptance of HFNC and the availability of devices and accessories designed for neonatal, pediatric, and adult patients are further expanding its application across healthcare settings.
“By application, acute respiratory failure segment to lead market during forecast period”
Acute respiratory failure holds the largest share of the HFNC market by application, primarily due to the increasing use of HFNC for patients requiring immediate non-invasive respiratory support. HFNC delivers heated and humidified oxygen at high flow rates, helping improve oxygenation, reduce the work of breathing, and relieve respiratory distress. Its growing clinical acceptance for managing acute hypoxemic respiratory failure has increased its utilization across intensive care units, emergency departments, and other acute-care settings.
The rising incidence of pneumonia, pulmonary infections, acute respiratory distress, and exacerbations of underlying cardiopulmonary conditions is further driving demand for HFNC in this application. Moreover, the increasing preference for non-invasive respiratory support and the potential for HFNC to prevent or delay invasive mechanical ventilation in appropriate patients are contributing to the segment’s dominant position in the market.
“By end user, hospitals segment to lead market during forecast period”
Hospitals hold the largest share of the HFNC market by end user, primarily due to the extensive use of HFNC therapy in intensive care units, emergency departments, respiratory wards, and post-operative care. Hospitals manage a high volume of patients with acute hypoxemic respiratory failure, pneumonia, and other respiratory conditions requiring advanced oxygen and non-invasive respiratory support, making them the primary users of HFNC systems. The availability of specialized critical-care infrastructure, continuous patient monitoring, trained healthcare professionals, and reliable oxygen-delivery systems further facilitates the widespread adoption of HFNC in hospitals. In addition, the growing use of HFNC for post-extubation support, pre-oxygenation, perioperative respiratory management, and emergency care is expected to further strengthen the hospitals segment’s leading position in the market.
“By region, North America accounted for largest market share in 2025”
The HFNC market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is estimated to account for the largest share of the global HFNC market, driven by its advanced healthcare infrastructure, high adoption of innovative respiratory care technologies, and increasing burden of respiratory diseases. The region benefits from the presence of established HFNC manufacturers, widespread use of non-invasive respiratory support in intensive care and emergency settings, and relatively high healthcare expenditure. Furthermore, growing awareness among healthcare professionals regarding the clinical benefits of HFNC, along with its expanding application in hospitals, critical care units, and post-operative care, is supporting continued market growth and strengthening North America’s leading position.
Key Market Players:
The key players in the HFNC market include Fisher & Paykel Healthcare Limited (New Zealand), Vapotherm (US), ResMed (US), Hamilton Medical AG (Switzerland), and Drägerwerk AG & Co. KGaA (Germany).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the High Flow Nasal Cannula Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
